Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective

Giron, Fanny; Quigley, Eamonn Martin

doi:10.5056/jnm18004

Cited by 14 publications

(12 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Significant evidence supports the relationship between the gut microbiome, inflammation, host response, and health (Pedersen et al, 2016;Dinan and Cryan, 2017;Kelly et al, 2017;Giron and Quigley, 2018). Disruption of the microbiome can lead to changes in microbial metabolism and consequently host metabolism (Belizario et al, 2018).…”

Section: Introductionmentioning

confidence: 94%

Oral Administration of Heat-Treated Lactobacilli Modifies the Murine Microbiome and Reduces Citrobacter Induced Colitis

et al. 2020

View full text Add to dashboard Cite

Significant evidence supports a relationship between the gut microbiome, inflammation, host response, and health, including the finding that a number of disorders are associated with disruption of the microbiome. In these disorders, a number of dietary interventions (including prebiotics, live probiotics, or heat-killed microbes) have been proposed to be curative or preventative agents. The use of heat-killed microbes has a number of benefits over living organisms, including reduced infection risk in vulnerable individuals, extended shelf life and the potential for use in combination with antimicrobial agents. We previously reported that murine chow supplemented with 5% ADR-159, a heat-treated fermentate generated by two Lactobacillus strains, altered both behavior and the microbiome of male mice. Now we show that ADR-159 fed female mice also display a similar microbiome shift as determined by 16S rDNA analysis. In particular, we observed a reduction of levels of Turicibacter and Clostridium sensu stricto. These subtle changes in the bacterial component of the microbiome were mirrored by changes in the virome. Extended consumption of the ADR-159 diet had no negative effect on general health and lipocalin 2 levels (LCN2; a proxy for inflammation), but we observed increased IL-17f and decreased IL-12α expression in the colon and decreased short chain fatty acid levels in the ADR-159 fed animals. Four weeks into the diet, half of the animals were dosed with Citrobacter to determine the effect of ADR-159 on infection and on pathogen induced colitis. Overall, our results suggest that while the ADR-159 diet does not prevent Citrobacter infection, it had an effect on Citrobacter-induced inflammation. In contrast to animals fed standard chow, ADR-159 fed animals did not show a reduction of small intestine length and increase of colon crypt depth, which occurred in control mice. These microbiological, histological, and immunological results provide evidence to support the impact of heat-treated microorganisms and their metabolites on the murine microbiome and health.

show abstract

Section: Introductionmentioning

confidence: 94%

Oral Administration of Heat-Treated Lactobacilli Modifies the Murine Microbiome and Reduces Citrobacter Induced Colitis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…longum 35624 [42], пробиотика, широко используемого в лечении симптомов СРК. При описании полного генома этой бактерии исследователи идентифицировали конкретный кластер генов, который кодировал механизм, необходимый для синтеза экзополисахаридной (EPS) оболочки, которая имеет противовоспалительную активность [43,44]. Другим фундаментальным компонентом нынешнего определения пробиотика является то, что это живой организм [45] и он выживает при транзите через желудочно-кишечный тракт [46].…”

Section: Bifidobacterium Longum Subsp Longum 35624 в лечении сркunclassified

Unique strain of Bifidobacterium longum and its efficacy in irritable bowel syndrome

Плотникова

2021

Medicinskij sovet

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is one of the most prevalent gastrointestinal disorders affecting between 5 and 15% of the general adult population worldwide. Over the course of many years altered intestinal motility, visceral hypersensitivity, immune changes and, as it has recently been found, impaired epithelial barrier function were meant to explain the origin of symptoms in the IBS. We have come to realize now that the IBS warrants serious clinical and scientific study. Not that long ago, the connections between the gut and the brain have been expanded to include a new entrant, the microbiota, resulting in the creation of a new concept of a microbiota-gut-brain axis.Microbiota is a risk factor for the irritable bowel syndrome. Probiotics are defined as live microorganisms, which can alter the intestinal flora and regulate intestinal functions such as reduction of visceral hypersensitivity, improvement of mucosal barrier function, modulate immune responses and chronic inflammation, affect the central nervous system, gastrointestinal motility, etc. The correctness of this approach is confirmed by several studies of the probiotic Bifidobacterium longum subsp. longum 35624, which is widely used in the treatment of symptoms of irritable bowel syndrome. The dietary supplement Bifidobacterium longum subsp. longum 35624 contains 1 × 109 colony-forming units, which provides a clinically effective level of these beneficial bacteria. Bifidobacterium longum subsp. longum 35624 also reduces inflammation in the gastrointestinal tract and has positive results in reducing abdominal symptoms (e.g. abdominal pain / discomfort and bloating) associated with the irritable bowel syndrome and other conditions.

show abstract

“…It has been suggested that pharmabiotics include pharmaceutical probiotics with specific evidence of generating health benefits and with proven positive physiological effects, or with the capacity to play a pharmacological role in diseases. 15,16 Hence, pharmabiotics comply with two criteria: 16 (a) they provide physiological and pharmacological health benefits against diseases; and (b) they serve as prevention and treatment for medical conditions.…”

Section: Pharmabioticmentioning

confidence: 99%

Lactobacillus acidophilus LB: a useful pharmabiotic for the treatment of digestive disorders

Troche

Adame

Díaz

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Dysbiosis, a loss of balance between resident bacterial communities and their host, is associated with multiple diseases, including inflammatory bowel diseases (nonspecific chronic ulcerative colitis and Crohn’s disease), and digestive functional disorders. Probiotics, prebiotics, synbiotic organisms and, more recently, pharmabiotics, have been shown to modulate the human microbiota. In this review, we provide an overview of the key concepts relating to probiotics, prebiotics, synbiotic organisms, and pharmabiotics, with a focus on available clinical evidence regarding the specific use of a unique pharmabiotic, the strain Lactobacillus acidophilus LB ( Lactobacillus boucardii), for the management of gastrointestinal disorders. Since it does not contain living organisms, the administration of L. acidophilus LB is effective and safe as an adjuvant in the treatment of acute diarrhea, chronic diarrhea, and antibiotic-associated diarrhea, even in the presence of immunosuppression.

show abstract

Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective

Cited by 14 publications

References 108 publications

Oral Administration of Heat-Treated Lactobacilli Modifies the Murine Microbiome and Reduces Citrobacter Induced Colitis

Oral Administration of Heat-Treated Lactobacilli Modifies the Murine Microbiome and Reduces Citrobacter Induced Colitis

Unique strain of Bifidobacterium longum and its efficacy in irritable bowel syndrome

Lactobacillus acidophilus LB: a useful pharmabiotic for the treatment of digestive disorders

Contact Info

Product

Resources

About